Tags

Type your tag names separated by a space and hit enter

Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial.
J Pain Symptom Manage 2004; 27(5):460-70JP

Abstract

The analgesic efficacy of the cyclooxygenase-2 specific inhibitors, valdecoxib and rofecoxib, were evaluated in patients following oral surgery. In a randomized, double-blind, controlled trial, patients experiencing moderate or severe pain received single-dose valdecoxib 40 mg (n=99), rofecoxib 50 mg (n=101), or placebo (n=50) within 4 hours after multiple third molar extraction with bone removal. Onset of action was significantly faster with valdecoxib 40 mg (30 minutes) compared with rofecoxib 50 mg (45 minutes), as measured by pain intensity difference and pain relief scores (P <or= 0.05). Valdecoxib and rofecoxib provided a similar magnitude of analgesic effect, as measured by time-weighted sum of total pain relief, at 6 hours post dosing. However, valdecoxib was significantly superior to rofecoxib with respect to mean time-specific pain intensity difference and pain relief scores from 30 minutes to 1.5 hours post dose (P < 0.05). All treatments were well tolerated.

Authors+Show Affiliations

Wasatch Oral Surgery, West Jordan, Salt Lake City, Utah, USA.No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15120774

Citation

Christensen, Kyle S., and Gail D. Cawkwell. "Valdecoxib Versus Rofecoxib in Acute Postsurgical Pain: Results of a Randomized Controlled Trial." Journal of Pain and Symptom Management, vol. 27, no. 5, 2004, pp. 460-70.
Christensen KS, Cawkwell GD. Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. J Pain Symptom Manage. 2004;27(5):460-70.
Christensen, K. S., & Cawkwell, G. D. (2004). Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. Journal of Pain and Symptom Management, 27(5), pp. 460-70.
Christensen KS, Cawkwell GD. Valdecoxib Versus Rofecoxib in Acute Postsurgical Pain: Results of a Randomized Controlled Trial. J Pain Symptom Manage. 2004;27(5):460-70. PubMed PMID: 15120774.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. AU - Christensen,Kyle S, AU - Cawkwell,Gail D, PY - 2003/10/07/accepted PY - 2004/5/4/pubmed PY - 2004/7/9/medline PY - 2004/5/4/entrez SP - 460 EP - 70 JF - Journal of pain and symptom management JO - J Pain Symptom Manage VL - 27 IS - 5 N2 - The analgesic efficacy of the cyclooxygenase-2 specific inhibitors, valdecoxib and rofecoxib, were evaluated in patients following oral surgery. In a randomized, double-blind, controlled trial, patients experiencing moderate or severe pain received single-dose valdecoxib 40 mg (n=99), rofecoxib 50 mg (n=101), or placebo (n=50) within 4 hours after multiple third molar extraction with bone removal. Onset of action was significantly faster with valdecoxib 40 mg (30 minutes) compared with rofecoxib 50 mg (45 minutes), as measured by pain intensity difference and pain relief scores (P <or= 0.05). Valdecoxib and rofecoxib provided a similar magnitude of analgesic effect, as measured by time-weighted sum of total pain relief, at 6 hours post dosing. However, valdecoxib was significantly superior to rofecoxib with respect to mean time-specific pain intensity difference and pain relief scores from 30 minutes to 1.5 hours post dose (P < 0.05). All treatments were well tolerated. SN - 0885-3924 UR - https://www.unboundmedicine.com/medline/citation/15120774/Valdecoxib_versus_rofecoxib_in_acute_postsurgical_pain:_results_of_a_randomized_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0885392404000661 DB - PRIME DP - Unbound Medicine ER -